This led to the development of higher-dose versions of GLP-1 drugs specifically for obesity: Saxenda was approved for weight loss in 2014 and then Wegovy was approved in 2021, demonstrating even more dramatic weight loss results
Nei pazienti con diabete di tipo 2, questi farmaci aiutano anche a migliorare il controllo della glicemia, sempre allinterno di un percorso terapeutico stabilito dal medico
October 10th, 2025: New Study Suggests Ozempic May Interfere With Critical Cancer Imaging New research suggests that GLP-1 weight-loss drugs such as Ozempic, Wegovy, and Mounjaro may interfere with PET-CT scan accuracy by altering how the bodys tissues absorb radioactive tracers
If you havent checked your insurance plan recently, now is a good time to do so
Taken together, the evidence is clear: microdoses of GLP-1 paired with microhabits can unlock outsized health benefits
A: Nosubcutaneous absorption is consistent across injection sites (abdomen, thigh, arm)
